Literature DB >> 26218637

Salvage of nicotinamide adenine dinucleotide plays a critical role in the bioenergetic recovery of post-hypoxic cardiomyocytes.

Domokos Gero1, Csaba Szabo1.   

Abstract

BACKGROUND AND
PURPOSE: Ischaemic heart disease can lead to serious, life-threatening complications. Traditional therapies for ischaemia aim to increase oxygen delivery and reduce the myocardial ATP consumption by increasing the coronary perfusion and by suppressing cardiac contractility, heart rate or blood pressure. An adjunctive treatment option for ischaemia is to improve or optimize myocardial metabolism. EXPERIMENTAL APPROACH: Metabolic suppression in the ischaemic heart is characterized by reduced levels of high-energy molecules: ATP and NAD(+) . Because NAD(+) is required for most metabolic processes that generate ATP, we hypothesized that restoration of NAD(+) would be a prerequisite for ATP regeneration and examined the role of the major NAD(+) anabolic and catabolic pathways in the bioenergetic restoration process following oxygen-glucose deprivation injury in a cardiomyocyte cell line (H9c2 cells). KEY
RESULTS: Salvage of NAD(+) via nicotinamide phosphoribosyl transferase was essential for bioenergetic recovery in cardiomyocytes. Blockade of nicotinamide phosphoribosyl transferase prevented the restoration of the cellular ATP pool following oxygen-glucose deprivation injury by inhibiting both the aerobic and anaerobic metabolism in the cardiomyocytes. NAD(+) consumption by PARP-1 also undermined the recovery processes, and PARP inhibition significantly improved the metabolism and increased cellular ATP levels in cardiomyocytes. CONCLUSIONS AND IMPLICATIONS: We conclude that the NAD(+) salvage pathway is essential for bioenergetic recovery in post-hypoxic cardiomyocytes and PARP inhibition may represent a potential future therapeutic intervention in ischaemic heart disease.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26218637      PMCID: PMC4621988          DOI: 10.1111/bph.13252

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  57 in total

1.  PARP inhibitors bounce back.

Authors:  Ken Garber
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

2.  Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size.

Authors:  Jan P Roesner; Jan Mersmann; Stefan Bergt; Karl Bohnenberg; Carmen Barthuber; Csaba Szabo; Gabriele E F Nöldge-Schomburg; Kai Zacharowski
Journal:  Shock       Date:  2010-05       Impact factor: 3.454

3.  Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences.

Authors:  L Liaudet; L Timashpolsky; L Virág; A Cziráki; C Szabó
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction.

Authors:  Fabrizio Montecucco; Inga Bauer; Vincent Braunersreuther; Santina Bruzzone; Alexander Akhmedov; Thomas F Lüscher; Timo Speer; Alessandro Poggi; Elena Mannino; Graziano Pelli; Katia Galan; Maria Bertolotto; Sébastien Lenglet; Anna Garuti; Christophe Montessuit; René Lerch; Corinne Pellieux; Nicolas Vuilleumier; Franco Dallegri; Jacqueline Mage; Carlos Sebastian; Raul Mostoslavsky; Angèle Gayet-Ageron; Franco Patrone; François Mach; Alessio Nencioni
Journal:  Antioxid Redox Signal       Date:  2012-05-14       Impact factor: 8.401

5.  Activation of the poly(ADP-ribose) polymerase pathway in human heart failure.

Authors:  Andrea Molnár; Attila Tóth; Zsolt Bagi; Zoltán Papp; István Edes; Miklós Vaszily; Zoltán Galajda; Julius Gy Papp; András Varró; Viktória Szüts; Zsombor Lacza; Domokos Gerö; Csaba Szabó
Journal:  Mol Med       Date:  2006 Jul-Aug       Impact factor: 6.354

6.  Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass.

Authors:  Gábor Szabó; Pál Soós; Susanne Bährle; Zsuzsanna Zsengellér; Christa Flechtenmacher; Siegfried Hagl; Csaba Szabó
Journal:  Eur J Cardiothorac Surg       Date:  2004-05       Impact factor: 4.191

7.  A plate reader method for the measurement of NAD, NADP, glutathione, and ascorbate in tissue extracts: Application to redox profiling during Arabidopsis rosette development.

Authors:  Guillaume Queval; Graham Noctor
Journal:  Anal Biochem       Date:  2007-01-10       Impact factor: 3.365

8.  A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial.

Authors:  David A Morrow; Chaim M Brickman; Sabina A Murphy; Kenneth Baran; Ricardo Krakover; Harold Dauerman; Sujatha Kumar; Natanya Slomowitz; Laura Grip; Carolyn H McCabe; Andrew L Salzman
Journal:  J Thromb Thrombolysis       Date:  2008-06-06       Impact factor: 2.300

Review 9.  New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2004-02-15       Impact factor: 10.787

10.  Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction.

Authors:  Domokos Gerö; Petra Szoleczky; Kunihiro Suzuki; Katalin Módis; Gabor Oláh; Ciro Coletta; Csaba Szabo
Journal:  Diabetes       Date:  2012-12-07       Impact factor: 9.461

View more
  8 in total

1.  Foetal hypoxia impacts methylome and transcriptome in developmental programming of heart disease.

Authors:  Lei Huang; Xin Chen; Chiranjib Dasgupta; Wanqiu Chen; Rui Song; Charles Wang; Lubo Zhang
Journal:  Cardiovasc Res       Date:  2019-07-01       Impact factor: 10.787

2.  Exogenous supplemental NAD+ protect myocardium against myocardial ischemic/reperfusion injury in swine model.

Authors:  Xinrong Zhai; Wenzheng Han; Ming Wang; Shaofeng Guan; Xinkai Qu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

3.  Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant.

Authors:  Isabel López-García; Domokos Gerő; Bartosz Szczesny; Petra Szoleczky; Gabor Olah; Katalin Módis; Kangling Zhang; Jungling Gao; Ping Wu; Lawrence C Sowers; Doug DeWitt; Donald S Prough; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2016-11-15       Impact factor: 8.739

4.  Salvage of nicotinamide adenine dinucleotide plays a critical role in the bioenergetic recovery of post-hypoxic cardiomyocytes.

Authors:  Domokos Gero; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2015-10-14       Impact factor: 8.739

5.  Nicotinamide mononucleotide preserves mitochondrial function and increases survival in hemorrhagic shock.

Authors:  Carrie A Sims; Yuxia Guan; Sarmistha Mukherjee; Khushboo Singh; Paul Botolin; Antonio Davila; Joseph A Baur
Journal:  JCI Insight       Date:  2018-09-06

6.  Longevity pathways in stress resistance: targeting NAD and sirtuins to treat the pathophysiology of hemorrhagic shock.

Authors:  Carrie A Sims; Hanna E Labiner; Sohini S Shah; Joseph A Baur
Journal:  Geroscience       Date:  2021-01-18       Impact factor: 7.713

7.  Glucocorticoids Suppress Mitochondrial Oxidant Production via Upregulation of Uncoupling Protein 2 in Hyperglycemic Endothelial Cells.

Authors:  Domokos Gerö; Csaba Szabo
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

8.  The novel mitochondria-targeted hydrogen sulfide (H2S) donors AP123 and AP39 protect against hyperglycemic injury in microvascular endothelial cells in vitro.

Authors:  Domokos Gerő; Roberta Torregrossa; Alexis Perry; Alicia Waters; Sophie Le-Trionnaire; Jacqueline L Whatmore; Mark Wood; Matthew Whiteman
Journal:  Pharmacol Res       Date:  2016-08-23       Impact factor: 7.658

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.